We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated
between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active …

Despite more than half a century of use in leishmaniasis, antimony therapy still presents
serious problems concerning dosage and toxicity. Low and high doses have been shown to …

We investigated factors associated with treatment failure in the treatment of cutaneous
leishmaniasis with meglumine antimony in a reference service in Mato Grosso State. A …

With the aim of comparing the therapeutic efficacy, tolerability and toxicity of meglumine
antimoniate, aminosidine sulphate and pentamidine isethionate, a field study was …

INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for
over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results …

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …

We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in
24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with …

We conducted a quasi-experimental study to compare the response to meglumine
antimoniate in patients with localized cutaneous leishmaniasis from two endemic areas of …

Although intralesional meglumine antimoniate (MA) infiltration is considered an option for
cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been …

Clinical response to supervised treatment of Colombian patients with cutaneous
leishmaniasis was evaluated in a randomized controlled trial comparing 10 days versus 20 …